Treatment with interleukin (IL)-6 inhibitor tocilizumab improves anaemia markers in patients with rheumatoid arthritis (RA) compared with other disease-modifying antirheumatic drugs (DMARDs), real-world data have shown.
In low- and middle-income countries (LMICs), lifetime self-reported arthritis is significantly associated with mental health comorbidities like depression subtypes and anxiety, a recent study has shown.
Patients with systemic lupus erythematosus (SLE) without cardiovascular conditions have impaired endothelial function, a new case-controlled study has shown. Factors that contribute to endothelial dysfunction include renal diseases and diastolic hypertension.
The use of biological disease-modifying antirheumatic drugs (bDMARD) is associated with a minimal disease activity (MDA) status and remission in patients with psoriatic arthritis (PsA) as compared to conventional synthetic (cs)DMARD, according to a recent study.
Low lean mass, either alone or in combination with high percentage fat mass, increases the risk of fragility in Korean males, a new study shows. In Korean females, body composition does not appear to be associated with fracture risk.
The prevalence of cardiovascular diseases (CVDs) is higher in rheumatoid arthritis, psoriasis and systemic lupus erythematosus than in other immune-mediated inflammatory diseases, a new cross-sectional analysis has shown.
Current statin use does not contribute to an increased risk of developing systemic lupus erythematosus in individuals aged 40 years or above, according to a population-based cohort study. There is rather a signal of protection against the risk among long-term statin users.
Compared with other models of care, nurse-led care (NLC) for patients with rheumatoid arthritis (RA) is effective, acceptable and safe, according to a recent study. However, current evidence is limited to draw conclusions on its accessibility, appropriateness and efficiency.
Sleep disorders commonly occur in patients with ankylosing spondylitis (AS), particularly those with high disease activity, a study has found. Furthermore, treatment with antitumour necrosis factor (anti-TNF)-α improves sleep quality but not polysomnography parameters.
The use of hydroxychloroquine (HCQ) and low-dose aspirin (ASA) appears to improve systemic lupus erythematosus (SLE), according to a recent study. This finding supports its continued use in patients with SLE.
Patients with rheumatoid arthritis (RA) who did not respond adequately to a tumour necrosis factor α (TNF-α) inhibitor derived better benefit from treatment with a non-TNF-targeted biologic drug over a second anti-TNF drug, a recent study suggested.